Literature DB >> 21625338

An Update on the Biology of RAS/RAF Mutations in Colorectal Cancer.

Mandayam O Nandan1, Vincent W Yang.   

Abstract

Deaths caused by colorectal cancer (CRC) are among the leading causes of cancer-related death in the United States and around the world. Approximately 150,000 Americans are diagnosed with CRC each year and around 50,000 will die from it. Mutations in many key genes have been identified that are important to the pathogenesis of CRC. Among the genes mutated in CRC, RAS and RAF mutations are common events. Both RAS and RAF are critical mediators of the mitogen-activated protein kinase (MAPK) pathway that is involved in regulating cellular homeostasis, including proliferation, survival, and differentiation. In this review, we provide a historical perspective and update on RAS/RAF mutations as related to colorectal cancer. Additionally, we will review recent mouse models of RAS and RAF mutations that have an impact on CRC research.

Entities:  

Year:  2011        PMID: 21625338      PMCID: PMC3103074          DOI: 10.1007/s11888-011-0086-1

Source DB:  PubMed          Journal:  Curr Colorectal Cancer Rep        ISSN: 1556-3790


  65 in total

1.  Detection of high incidence of K-ras oncogenes during human colon tumorigenesis.

Authors:  K Forrester; C Almoguera; K Han; W E Grizzle; M Perucho
Journal:  Nature       Date:  1987 May 28-Jun 3       Impact factor: 49.962

2.  Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization.

Authors:  Mathew J Garnett; Sareena Rana; Hugh Paterson; David Barford; Richard Marais
Journal:  Mol Cell       Date:  2005-12-22       Impact factor: 17.970

3.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

Review 4.  Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.

Authors:  Jared A Gollob; Scott Wilhelm; Chris Carter; Susan L Kelley
Journal:  Semin Oncol       Date:  2006-08       Impact factor: 4.929

5.  K-ras is essential for the development of the mouse embryo.

Authors:  K Koera; K Nakamura; K Nakao; J Miyoshi; K Toyoshima; T Hatta; H Otani; A Aiba; M Katsuki
Journal:  Oncogene       Date:  1997-09-04       Impact factor: 9.867

6.  Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses.

Authors:  C J Der; T G Krontiris; G M Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  1982-06       Impact factor: 11.205

7.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

Authors:  M Serrano; A W Lin; M E McCurrach; D Beach; S W Lowe
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

8.  Telomeres shorten during ageing of human fibroblasts.

Authors:  C B Harley; A B Futcher; C W Greider
Journal:  Nature       Date:  1990-05-31       Impact factor: 49.962

Review 9.  Modelling oncogenic Ras/Raf signalling in the mouse.

Authors:  Florian A Karreth; David A Tuveson
Journal:  Curr Opin Genet Dev       Date:  2009-02-07       Impact factor: 5.578

10.  Germline KRAS mutations cause Noonan syndrome.

Authors:  Suzanne Schubbert; Martin Zenker; Sara L Rowe; Silke Böll; Cornelia Klein; Gideon Bollag; Ineke van der Burgt; Luciana Musante; Vera Kalscheuer; Lars-Erik Wehner; Hoa Nguyen; Brian West; Kam Y J Zhang; Erik Sistermans; Anita Rauch; Charlotte M Niemeyer; Kevin Shannon; Christian P Kratz
Journal:  Nat Genet       Date:  2006-02-12       Impact factor: 38.330

View more
  11 in total

1.  RAS signaling pathways, mutations and their role in colorectal cancer.

Authors:  Kypros Zenonos; Katy Kyprianou
Journal:  World J Gastrointest Oncol       Date:  2013-05-15

2.  Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer.

Authors:  Todd M Pitts; Timothy P Newton; Erica L Bradshaw-Pierce; Rebecca Addison; John J Arcaroli; Peter J Klauck; Stacey M Bagby; Stephanie L Hyatt; Alicia Purkey; John J Tentler; Aik Choon Tan; Wells A Messersmith; S Gail Eckhardt; Stephen Leong
Journal:  PLoS One       Date:  2014-11-17       Impact factor: 3.240

3.  Miniaturized Real-Time PCR on a Q3 System for Rapid KRAS Genotyping.

Authors:  Maria Guarnaccia; Rosario Iemmolo; Salvatore Petralia; Sabrina Conoci; Sebastiano Cavallaro
Journal:  Sensors (Basel)       Date:  2017-04-11       Impact factor: 3.576

4.  Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.

Authors:  Peter J Klauck; Stacey M Bagby; Anna Capasso; Erica L Bradshaw-Pierce; Heather M Selby; Anna Spreafico; John J Tentler; Aik Choon Tan; Jihye Kim; John J Arcaroli; Alicia Purkey; Wells A Messersmith; Keisuke Kuida; S Gail Eckhardt; Todd M Pitts
Journal:  BMC Cancer       Date:  2018-02-05       Impact factor: 4.430

5.  Inducible Intestine-Specific Expression of krasV12 Triggers Intestinal Tumorigenesis In Transgenic Zebrafish.

Authors:  Jeng-Wei Lu; Divya Raghuram; Pei-Shi Angelina Fong; Zhiyuan Gong
Journal:  Neoplasia       Date:  2018-11-01       Impact factor: 5.715

6.  Molecular characterization of colorectal cancer using whole-exome sequencing in a Taiwanese population.

Authors:  Ya-Sian Chang; Chien-Chin Lee; Tao-Wei Ke; Chieh-Min Chang; Dy-San Chao; Hsi-Yuan Huang; Jan-Gowth Chang
Journal:  Cancer Med       Date:  2019-05-24       Impact factor: 4.452

7.  Gastrodin Exerts Cardioprotective Action via Inhibition of Insulin-Like Growth Factor Type 2/Insulin-Like Growth Factor Type 2 Receptor Expression in Cardiac Hypertrophy.

Authors:  Jun Lu; Xin Ma; Wen-Cong Gao; Xin Zhang; Yuanling Fu; Qian Liu; Lixiang Tian; Xiao-Dan Qin; Weimin Yang; Hong-Yi Zheng; Chang-Bo Zheng
Journal:  ACS Omega       Date:  2021-06-21

8.  K-Ras gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoing irinotecan- or oxaliplatin-based chemotherapy.

Authors:  Rafał Stec; Lubomir Bodnar; Radosław Charkiewicz; Jan Korniluk; Marta Rokita; Marta Smoter; Marzena Ciechowicz; Lech Chyczewski; Jacek Nikliński; Wojciech Kozłowski; Cezary Szczylik
Journal:  Cancer Biol Ther       Date:  2012-08-22       Impact factor: 4.742

Review 9.  Modeling adaptive drug resistance of colorectal cancer and therapeutic interventions with tumor spheroids.

Authors:  Astha Lamichhane; Pradip Shahi Thakuri; Pouria Rafsanjani Nejad; Hossein Tavana
Journal:  Exp Biol Med (Maywood)       Date:  2021-06-08

Review 10.  Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status.

Authors:  Ozkan Kanat; Hulya Ertas; Burcu Caner
Journal:  World J Clin Cases       Date:  2018-10-06       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.